RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) but lowers the price target from $56 to $55.
March 01, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Xenon Pharmaceuticals but lowers the price target from $56 to $55.
The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. This could lead to a neutral short-term impact on the stock as the market digests the minor adjustment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100